BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35727602)

  • 1. Membrane-Anchored and Tumor-Targeted IL12 (attIL12)-PBMC Therapy for Osteosarcoma.
    Yang Q; Hu J; Jia Z; Wang Q; Wang J; Dao LH; Zhang W; Zhang S; Xia X; Gorlick R; Li S
    Clin Cancer Res; 2022 Sep; 28(17):3862-3873. PubMed ID: 35727602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors.
    Hu J; Yang Q; Zhang W; Du H; Chen Y; Zhao Q; Dao L; Xia X; Natalie Wall F; Zhang Z; Mahadeo K; Gorlick R; Kopetz S; Dotti G; Li S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35027427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models.
    Hu J; Lazar AJ; Ingram D; Wang WL; Zhang W; Jia Z; Ragoonanan D; Wang J; Xia X; Mahadeo K; Gorlick R; Li S
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38199607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
    Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
    J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
    Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
    BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines.
    Jia Z; Ragoonanan D; Mahadeo KM; Gill J; Gorlick R; Shpal E; Li S
    Front Immunol; 2022; 13():952231. PubMed ID: 36203573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
    Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T targets and microenvironmental barriers of osteosarcoma.
    Zhu J; Simayi N; Wan R; Huang W
    Cytotherapy; 2022 Jun; 24(6):567-576. PubMed ID: 35193828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.
    Talbot LJ; Chabot A; Funk A; Nguyen P; Wagner J; Ross A; Tillman H; Davidoff A; Gottschalk S; DeRenzo C
    Front Immunol; 2021; 12():691741. PubMed ID: 34211478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
    Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma.
    Meister H; Look T; Roth P; Pascolo S; Sahin U; Lee S; Hale BD; Snijder B; Regli L; Ravi VM; Heiland DH; Sentman CL; Weller M; Weiss T
    Clin Cancer Res; 2022 Nov; 28(21):4747-4756. PubMed ID: 36037304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating osteosarcoma with CAR T cells.
    Köksal H; Müller E; Inderberg EM; Bruland Ø; Wälchli S
    Scand J Immunol; 2019 Mar; 89(3):e12741. PubMed ID: 30549299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
    Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
    J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors.
    Murty S; Labanieh L; Murty T; Gowrishankar G; Haywood T; Alam IS; Beinat C; Robinson E; Aalipour A; Klysz DD; Cochran JR; Majzner RG; Mackall CL; Gambhir SS
    Cancer Res; 2020 Nov; 80(21):4731-4740. PubMed ID: 32958548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.
    Stroncek DF; Ren J; Lee DW; Tran M; Frodigh SE; Sabatino M; Khuu H; Merchant MS; Mackall CL
    Cytotherapy; 2016 Jul; 18(7):893-901. PubMed ID: 27210719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
    Hillerdal V; Essand M
    BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.